Literature DB >> 6137236

Diacetyl nadolol: 3-month ocular hypotensive effect in glaucomatous eyes.

E Duzman, N Rosen, M Lazar.   

Abstract

In a double-masked, 3-month clinical study the ocular hypotensive effects of diacetyl nadolol (DAN), timolol, and nadolol were compared. When applied topically to the eyes of glaucomatous patients timolol 0.5% was found to be significantly more effective than DAN 2% in controlling IOP at 3 of 10 evaluation periods. Fewer patients, however, developed tolerance to DAN 2% than to timolol 0.5%. DAN 0.5% was also effective in lowering intraocular pressure in 3 of 8 patients tested. Nadolol 2% had no long-term ocular hypotensive effect. Two of 8 patients treated with DAN 2% developed a bilateral periorbital dermatitis and were removed from the study even though their intraocular pressures were well controlled. No other clinically significant local or systemic side effects were observed during the course of the study.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6137236      PMCID: PMC1040161          DOI: 10.1136/bjo.67.10.668

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  9 in total

1.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

2.  Dermatitis as side-effect of long-term metoprolol.

Authors:  H A Neumann; T Van Joost; W Westerhof
Journal:  Lancet       Date:  1979-10-06       Impact factor: 79.321

3.  Cutaneous and ocular reactions to practolol.

Authors:  R H Felix; F A Ive; M G Dahl
Journal:  Br Med J       Date:  1974-11-09

4.  Effect of nadolol in treatment of hypertension.

Authors:  L Volicer; C S Liang; H Gavras; C P Tifft; G R Kershaw; I Gavras; D L Griffith; R Vukovitch; H R Brunner
Journal:  J Clin Pharmacol       Date:  1979 Feb-Mar       Impact factor: 3.126

5.  Angina pectoris: effective therapy once daily.

Authors:  G Prager
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

6.  Initial experience with a new long-acting beta-blocker, nadolol, in hypertensive patients.

Authors:  G Hitzenberger
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

7.  Improved physical performance as a therapeutic objective in patients with angina.

Authors:  A S Ling; J T Groel
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

8.  Diacetyl derivative of nadolol. I. Ocular pharmacology and short-term ocular hypotensive effect in glaucomatous eyes.

Authors:  E Duzman; C C Chen; J Anderson; M Blumenthal; H Twizer
Journal:  Arch Ophthalmol       Date:  1982-12

9.  Cutaneous reactions to propranolol (Inderal).

Authors:  H A Jensen; H I Mikkelsen; S Wadskov; J Sondergaard
Journal:  Acta Med Scand       Date:  1976
  9 in total
  3 in total

Review 1.  Adverse effects of topical antiglaucomatous medications on the conjunctiva.

Authors:  D Broadway; I Grierson; R Hitchings
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

2.  A comparison of the effects of oral nadolol and topical timolol on intraocular pressure, blood pressure, and heart rate.

Authors:  G R Duff; A H Watt; P A Graham
Journal:  Br J Ophthalmol       Date:  1987-09       Impact factor: 4.638

3.  Penetration of nadolol into aqueous humour after a single oral dose.

Authors:  T H Tiong; S O Hung; M S Perelman
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.